• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Too much of a risk for Alzheimers Drug

Quote




anonymous said:
This is incorrect, as other posters have suggested. Full steam ahead for candidates that made the final phase with interviews resuming next week or week after. If you made it to the final phase, you would have received an email with total compensation package/range offered. You were only to respond if the range wasn’t acceptable. The recruiters wouldn’t have divulged that information that you suggested considering Biogen’s plans for the division. Whether or not someone chooses to take the risk is another issue and their choice. Good luck all
Click to expand...

3 posts in a row with the same verbiage, talking points and knowledge and re-statement of recruiter protocol.. hmmmm
 




anonymous said:
3 posts in a row with the same verbiage, talking points and knowledge and re-statement of recruiter protocol.. hmmmm
Click to expand...

let’s clarify. I am the poster of this that you’re suspicious of, and not the others. There are actually multiple credible posters sharing information. It’s easy to weed out the trolls, the pessimists and others that are pissed because they got passed over. None of us have a crystal ball. This could be a colossal flop, or a major win for patients. I don’t know and neither do you. I can tell you that my post is 100% accurate, so take it for what’s it worth. Biogen has a reason for doing what they are. Decisions being made are well above our respective pay grades. Good luck to you
 








anonymous said:
There is no question this drug will launch. The only question here is the timing of it all. Aug/Sept remains the goal to have all the hires on board. We’ll see.
Click to expand...
“No question” - I hope you are right, as an MS rep I have quite a bit of stock. I just read another article talking about the delay, but more disturbing the feeling this drug has a minimal chance for approval. According to the article other nearly identical molecules with similar very finite and cherry picked success all failed. This article said best case scenario is FDA demands more studies specifically with the few patients that drug had any impact and the drug is 3-5 years out if at all.
 




If you are truly a current Biogen rep you should be rooting for this drug to be a blockbuster. I mean who wishes failure on their current employer with all the stock and 401k money you seemingly would have there.
 




I’m not a current employee but in the industry. I’m hoping that the drug is approved and becomes and option for patients. I watched Alzheimer’s steak two people very close to me and would have done anything to get this drug or anything like it into their hands. Wishing Biogen a
Lot of luck and all those hoping to be part of it the best of success!
 








The company apparently feels confident enough to hire a new sales force by late summer/early fall of 2020. Recruitment process forging forward. You are fighting a losing battle with your anonymous attacks on here.
 




anonymous said:
The company apparently feels confident enough to hire a new sales force by late summer/early fall of 2020. Recruitment process forging forward. You are fighting a losing battle with your anonymous attacks on here.
Click to expand...
I was at a company that hired an entire sales force for an upcoming medicine, only to lay them off when the medicine was denied by the FDA. Biogen has laid off in the past, so don’t think they won’t again. It’s a risk/reward proposition.
 








anonymous said:
Thanks, genius.. Isn’t everything?
Click to expand...
I would agree with this. Just know, the risk on this is very high according to almost anyone outside Biogen. If you are going to take a risk like this, go to a small biotech where the reward is exponentially higher. The reward here is, at best, selling a very highly priced product with very, very modest efficacy in a large pharma model for a company who lays people off every 2-3 years.
 




anonymous said:
I would agree with this. Just know, the risk on this is very high according to almost anyone outside Biogen. If you are going to take a risk like this, go to a small biotech where the reward is exponentially higher. The reward here is, at best, selling a very highly priced product with very, very modest efficacy in a large pharma model for a company who lays people off every 2-3 years.
Click to expand...

We got it the very 1st time you posted it. No need to continually beat the dead horse over and over. Obviously you don’t like Biogen for either not hiring you or laying you off. Move on.
 




I hope the drug is approved because I have watched family members suffer the torture associated with Alzheimers Disease. I also have ex-colleagues who recently joined and hope for their sake the drug is approved and successful. I do wonder what type of restrictions and how many hoops insurers will make providers and patients jump through? Will testing be required to substantiate the disease and it's stage? If so, how expensive will it be? Who will pay for that? And please don't tell me that no insurers can deny coverage on this drug if it's approved. There are plenty of examples in multiple therapeutic areas where payers restrict and control usage. Good luck to all involved
 








anonymous said:
I was at a company that hired an entire sales force for an upcoming medicine, only to lay them off when the medicine was denied by the FDA. Biogen has laid off in the past, so don’t think they won’t again. It’s a risk/reward proposition.
Click to expand...


I got a call but now I am very reluctant to move ahead. If it is not approved, I will b e out the door
 




















Top Bottom
Back
Quote